Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 15/20 | 0.81 |
| ▸ | PRKDC | P78527 | 4/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | GSK3B | P49841 | 4/20 | 0.64 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.64 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.64 |
| ▸ | CDK2 | P24941 | 3/20 | 0.64 |
| ▸ | PRKCI | P41743 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2485557 | 0.90 | ATR (1.00) | ATRPRKDCCYP3A4ATM | |
| SCHEMBL6616666 | 0.87 | ATR (0.81) | ATRPRKDCCYP3A4GSK3BCCNE2 | |
| SCHEMBL6615544 | 0.84 | ATR (0.88) | ATRPRKDCCYP3A4GSK3BCCNE2 | |
| SCHEMBL6035902 | 0.83 | GSK3B (0.69) | ATRPRKDCCYP3A4GSK3BCCNE2 | |
| SCHEMBL6616728 | 0.83 | ATR (0.67) | ATRPRKDCCYP3A4GSK3BCCNE2 | |
| SCHEMBL6615738 | 0.83 | CCNE2 (0.68) | ATRCYP3A4GSK3BCCNE2CCNE1 | |
| SCHEMBL2484903 | 0.80 | ATR (1.00) | ATRPRKDCCYP3A4ATM | |
| SCHEMBL6616579 | 0.80 | ATR (0.66) | ATRCYP3A4GSK3BCCNE2CCNE1 | |
| SCHEMBL6618758 | 0.80 | ATR (0.63) | ATRPRKDCCYP3A4GSK3BCCNE2 | |
| SCHEMBL6616188 | 0.80 | ATR (0.68) | ATRCYP3A4GSK3BCCNE2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186113-A1 | Heterocyclic amines for the treatment of conditions associated with gsk-3 | ASTRAZENECA AB (SE) | 2004-09-23 | — | — | US | claimed |
| US-20040186113-A1 | Heterocyclic amines for the treatment of conditions associated with gsk-3 | ASTRAZENECA AB (SE) | 2004-09-23 | — | — | US | disclosed |
| EP-1406877-A1 | HETEROCYCLIC AMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003004475-A1 | HETEROCYCLIC AMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186113-A1 | Heterocyclic amines for the treatment of conditions associated with gsk-3 | GSK3A, GSK3B, PYGL | ATR 1381/4885PRKDC 897/4885CYP3A4 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.